This invention from the Australian Institute for Bioengineering and Nanotechnology at The University of Queensland helps to rapidly determine optimal conditions for selectively purifying Virus-Like Particles (VLPs) from VLP aggregates and misformed VLPs. It uses industry accepted reagents and precipitation methods, and overcomes the need for ultracentrifugation. The technology offers a range of advantages, including: lower cost; simplicity; high yield of VLPs of interest; does not require chromatography, can be readily packaged into a kit for optimization of purification conditions; and is scalable for clinical trial and market supply.

•  Licensing opportunities